ストックスクリーナーアプリを入手
22.05
0.05%
0.01
前日終値:
$22.04
開ける：
$22.37
24時間の取引高:
2.16M
Relative Volume:
0.78
時価総額：
$2.30B
収益：
$2.20B
当期純損益:
$-842.79M
株価収益率:
-2.6131
EPS:
-8.4382
ネットキャッシュフロー:
$-332.39M
1週間 パフォーマンス:
+6.68%
1か月 パフォーマンス:
-3.29%
6か月 パフォーマンス:
+25.00%
1年 パフォーマンス:
-52.83%
1日の値動き範囲:
$21.04
$22.66
1週間の範囲:
$20.56
$22.66
52週間の値動き範囲:
$10.41
$44.14
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
21.79 | 2.30B | 2.20B | -842.79M | -332.39M | -8.4382 |
VRTX
Vertex Pharmaceuticals Inc
|
428.12 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.22 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.76 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.58 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2025-12-09 | 開始されました | Wedbush | Outperform |
| 2025-11-05 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-09-22 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 開始されました | Bernstein | Mkt Perform |
| 2025-07-29 | 繰り返されました | H.C. Wainwright | Sell |
| 2025-07-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-07-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-07-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 開始されました | Citigroup | Sell |
| 2025-07-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-07-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-21 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-07-21 | ダウングレード | Needham | Hold → Underperform |
| 2025-07-21 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-18 | ダウングレード | Needham | Buy → Hold |
| 2025-06-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-06-17 | 開始されました | Wolfe Research | Peer Perform |
| 2025-06-16 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | ダウングレード | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
Sarepta Therapeutics Q1 2026 Earnings Preview — May 6, Street Expects $1.05 EPS - AlphaStreet
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Do Sarepta Therapeutics’ (SRPT) Bullish Earnings Forecasts and Vanguard Stake Hint at a Shifting Risk Profile? - Sahm
Sarepta (SRPT) Appoints New Acting Director for Biologics Evalua - GuruFocus
MSN Money - MSN
Vanguard Capital Management (NASDAQ: SRPT) reports 5.11% stake in Sarepta Therapeutics - Stock Titan
Sarepta Therapeutics (SRPT) price target decreased by 16.58% to 25.25 - MSN
Why is Sarepta Therapeutics (SRPT) up 24.2% since last earnings report? - MSN
Vanguard Portfolio Management (NASDAQ: SRPT) holds 6.75M shares (6.43%) - Stock Titan
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - Stock Traders Daily
M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket - MSN
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Sarepta Therapeutics stock sinks further Tuesday, after halting shipment of bestselling drug Elvidys - MSN
Sarepta’s Elevidys to Remain on Market With New FDA Warning - MSN
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating Biotech Volatility with Strategic Growth Potential - DirectorsTalk Interviews
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy - MSN
Sarepta Therapeutics Inc (HAM:AB3A) Stock Price, Trades & News - GuruFocus
Sarepta gains on data for muscular dystrophy therapies - MSN
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - msn.com
Sarepta cut to Underperform at BofA on Elevidys concerns - MSN
Sarepta to continue Elevidys shipments despite FDA request to halt - MSN
SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionSRPT - TMX Newsfile
[ARS] Sarepta Therapeutics, Inc. SEC Filing - Stock Titan
Sarepta Therapeutics (NASDAQ: SRPT) outlines 2026 equity and ESPP plus CEO transition - Stock Titan
Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy - MSN
Sarepta Loses Bid to Rehear Regenxbio DNA Patent Case Decision - Bloomberg Law News
Sarepta Therapeutics (SRPT) price target decreased by 10.97% to 22.48 - MSN
A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility - Yahoo Finance
Full Fed. Circ. Passes On Sarepta's Patent Rehearing Bid - Law360
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy - TradingView
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results - Business Wire
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Cwm LLC - MarketBeat
SRPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Opinion: As Duchenne innovation booms, let’s ensure it becomes real progress - BioSpace
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - TradingView
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring the Future of RNA-Targeted Therapeutics with Promising Forward P/E - DirectorsTalk Interviews
A Look At Sarepta Therapeutics (SRPT) Valuation After Roche’s New Global Elevidys Phase 3 Trial - Sahm
Technical Reactions to SRPT Trends in Macro Strategies - Stock Traders Daily
Roche plots route to EMA approval for DMD gene therapy - BioWorld News
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
DNA Patent Eligibility Under Spotlight in Sarepta’s En Banc Bid - Bloomberg Law News
SRPT Reiterated by HC Wainwright & Co. -- Rating Maintained at S - GuruFocus
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod - MSN
HC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
2.09%
大文字化:
|
ボリューム (24 時間):